The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

被引：2
作者：
Palaniyandi, Senthilnathan [1 ]
Kumari, Reena [1 ]
Strattan, Ethan [1 ,2 ]
Huang, Timothy [1 ]
Du, Jing [3 ]
Hakim, Natalya [3 ]
Kesler, Melissa V. [3 ]
Hildebrandt, Gerhard C. [1 ,2 ]
机构：
[1] Univ Kentucky, Dept Internal Med, Markey Canc Ctr, Div Hematol & Blood & Marrow Transplantat, Lexington, KY 40536 USA
[2] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY USA
[3] Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2020年 / 95卷 / 02期
关键词：
T-CELLS; INTEGRIN; ANTIBODY;
D O I：
10.1002/ajh.25678
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E39 / E41
页数：3
相关论文
共 10 条
  • [1] Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD
    Chen, Y-B
    McDonough, S.
    Chen, H.
    Kennedy, J.
    Illiano, C.
    Attar, E. C.
    Ballen, K. K.
    Dey, B. R.
    McAfee, S. L.
    Jagasia, M.
    Soiffer, R.
    Spitzer, T. R.
    Ritz, J.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (04) : 598 - 603
  • [2] Role of CXCR3-induced donor T-cell migration in acute GVHD
    Duffner, U
    Lu, B
    Hildebrandt, GC
    Teshima, T
    Williams, DL
    Reddy, P
    Ordemann, R
    Clouthier, SG
    Lowler, K
    Liu, C
    Gerard, C
    Cooke, KR
    Ferrara, JLM
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (10) : 897 - 902
  • [3] Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease
    Floisand, Yngvar
    Lundin, Knut E. A.
    Lazarevic, Vladimir
    Kristiansen, Jorn Dehli
    Osnes, Liv T. N.
    Tjonnfjord, Geir E.
    Reims, Henrik Mikael
    Gedde-Dahl, Tobias
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (01) : 172 - 175
  • [4] The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation
    Hill, GR
    Ferrara, JLM
    [J]. BLOOD, 2000, 95 (09) : 2754 - 2759
  • [5] Target antigens determine graft-versus-host disease phenotype
    Kaplan, DH
    Anderson, BE
    McNiff, JM
    Jain, D
    Shlomchik, MJ
    Shlomchik, WD
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (09) : 5467 - 5475
  • [6] LPAM(α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease
    Petrovic, A
    Alpdogan, O
    Willis, LM
    Eng, JM
    Greenberg, AS
    Kappel, BJ
    Liu, C
    Murphy, GJ
    Heller, G
    van den Brink, MRM
    [J]. BLOOD, 2004, 103 (04) : 1542 - 1547
  • [7] Picarella D, 1997, J IMMUNOL, V158, P2099
  • [8] The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
    Soler, Dulce
    Chapman, Tobias
    Yang, Li-Li
    Wyant, Tim
    Egan, Robert
    Fedyk, Eric R.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2009, 330 (03) : 864 - 875
  • [9] A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γc-/- double-mutant mice
    van Rijn, RS
    Simonetti, ER
    Hagenbeek, A
    Hogenes, MCH
    de Weger, RA
    Canninga-van Dijk, MR
    Weijer, K
    Spits, H
    Storm, G
    van Bloois, L
    Rijkers, G
    Martens, ACM
    Ebeling, SB
    [J]. BLOOD, 2003, 102 (07) : 2522 - 2531
  • [10] An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
    Wyant, Tim
    Fedyk, Eric
    Abhyankar, Brihad
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 (12) : 1437 - 1444
1